Tags

Type your tag names separated by a space and hit enter

Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women.
Breast Cancer Res Treat. 2005 Dec; 94(3):285-93.BC

Abstract

In this case-control study based on 250 women with breast cancer and 250 age-matched controls, we sought to evaluate the role of four polymorphic variants in the CYP1A1 gene in breast cancer susceptibility in Nigerian women. Heterozygosity for the CYP1A1 M1 genotype (CYP1A1 M1 [T/C]) was associated with a 21% reduced risk of breast cancer (OR = 0.79, 95% CI 0.46-1.40) while homozygosity for the genotype (CYP1A1 M1 [C/C]) conferred a non-significant 9% reduced risk of breast cancer. These risk profiles were not significantly altered in subgroup analysis by menopausal status. While heterozygosity for the CYP1A1 M3 genotype (T/C) conferred a non-significant 24% reduced risk of breast cancer (OR = 0.76, 95% CI 0.47-1.22), homozygosity for the variant was associated a non-significant 1.95-fold increased risk of breast cancer (OR = 1.95, 95% CI 0.24-6.01). Subgroup analysis showed a non-significant 11% reduced risk in premenopausal heterozygous carriers (OR = 0.89, 95% CI 0.45-1.44) and a non-significant 6% increased risk of postmenopausal breast cancer for carriers of the CYP1A1 M3 (T/C) genotype. The CYP1A1 M2 (isoleucine to valine) polymorphism in exon 7 and CYP1A1 M4 (threonine to asparagine) variant in codon 461 of the CYP1A1 gene were found to be very rare in our study subjects. This study has shown that while the CYP1A1 M1 polymorphism conferred reduced risk of breast cancer, homozygosity for the CYP1A1 M3 (C/C) was associated with increased risk of breast cancer although these risks did not attain statistical significance.

Authors+Show Affiliations

Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Room A521, Crabtree Hall, 130 Desoto Street, Pittsburgh, PA 15261, USA. michaelokobia@Yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

16254684

Citation

Okobia, Michael, et al. "Cytochrome P4501A1 Genetic Polymorphisms and Breast Cancer Risk in Nigerian Women." Breast Cancer Research and Treatment, vol. 94, no. 3, 2005, pp. 285-93.
Okobia M, Bunker C, Zmuda J, et al. Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women. Breast Cancer Res Treat. 2005;94(3):285-93.
Okobia, M., Bunker, C., Zmuda, J., Kammerer, C., Vogel, V., Uche, E., Anyanwu, S., Ezeome, E., Ferrell, R., & Kuller, L. (2005). Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women. Breast Cancer Research and Treatment, 94(3), 285-93.
Okobia M, et al. Cytochrome P4501A1 Genetic Polymorphisms and Breast Cancer Risk in Nigerian Women. Breast Cancer Res Treat. 2005;94(3):285-93. PubMed PMID: 16254684.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women. AU - Okobia,Michael, AU - Bunker,Clareann, AU - Zmuda,Joseph, AU - Kammerer,Candace, AU - Vogel,Victor, AU - Uche,Emmanuel, AU - Anyanwu,Stanley, AU - Ezeome,Emmanuel, AU - Ferrell,Robert, AU - Kuller,Lewis, Y1 - 2005/10/28/ PY - 2005/06/26/received PY - 2005/06/27/accepted PY - 2005/10/29/pubmed PY - 2006/4/28/medline PY - 2005/10/29/entrez SP - 285 EP - 93 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 94 IS - 3 N2 - In this case-control study based on 250 women with breast cancer and 250 age-matched controls, we sought to evaluate the role of four polymorphic variants in the CYP1A1 gene in breast cancer susceptibility in Nigerian women. Heterozygosity for the CYP1A1 M1 genotype (CYP1A1 M1 [T/C]) was associated with a 21% reduced risk of breast cancer (OR = 0.79, 95% CI 0.46-1.40) while homozygosity for the genotype (CYP1A1 M1 [C/C]) conferred a non-significant 9% reduced risk of breast cancer. These risk profiles were not significantly altered in subgroup analysis by menopausal status. While heterozygosity for the CYP1A1 M3 genotype (T/C) conferred a non-significant 24% reduced risk of breast cancer (OR = 0.76, 95% CI 0.47-1.22), homozygosity for the variant was associated a non-significant 1.95-fold increased risk of breast cancer (OR = 1.95, 95% CI 0.24-6.01). Subgroup analysis showed a non-significant 11% reduced risk in premenopausal heterozygous carriers (OR = 0.89, 95% CI 0.45-1.44) and a non-significant 6% increased risk of postmenopausal breast cancer for carriers of the CYP1A1 M3 (T/C) genotype. The CYP1A1 M2 (isoleucine to valine) polymorphism in exon 7 and CYP1A1 M4 (threonine to asparagine) variant in codon 461 of the CYP1A1 gene were found to be very rare in our study subjects. This study has shown that while the CYP1A1 M1 polymorphism conferred reduced risk of breast cancer, homozygosity for the CYP1A1 M3 (C/C) was associated with increased risk of breast cancer although these risks did not attain statistical significance. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/16254684/Cytochrome_P4501A1_genetic_polymorphisms_and_breast_cancer_risk_in_Nigerian_women_ L2 - https://doi.org/10.1007/s10549-005-9022-x DB - PRIME DP - Unbound Medicine ER -